These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

58 related items for PubMed ID: 11200057

  • 1. Tumor cell-derived TGF-beta and IL-10 dysregulate paclitaxel-induced macrophage activation.
    Mullins DW, Martins RS, Burger CJ, Elgert KD.
    J Leukoc Biol; 2001 Jan; 69(1):129-37. PubMed ID: 11200057
    [Abstract] [Full Text] [Related]

  • 2. Paclitaxel enhances macrophage IL-12 production in tumor-bearing hosts through nitric oxide.
    Mullins DW, Burger CJ, Elgert KD.
    J Immunol; 1999 Jun 01; 162(11):6811-8. PubMed ID: 10352302
    [Abstract] [Full Text] [Related]

  • 3. Interleukin-12 overcomes paclitaxel-mediated suppression of T-cell proliferation.
    Mullins DW, Koci MD, Burger CJ, Elgert KD.
    Immunopharmacol Immunotoxicol; 1998 Nov 01; 20(4):473-92. PubMed ID: 9805229
    [Abstract] [Full Text] [Related]

  • 4. Interleukin-4, interleukin-10, and interleukin-1-receptor antagonist but not transforming growth factor-beta induce ramification and reduce adhesion molecule expression of rat microglial cells.
    Wirjatijasa F, Dehghani F, Blaheta RA, Korf HW, Hailer NP.
    J Neurosci Res; 2002 Jun 01; 68(5):579-87. PubMed ID: 12111847
    [Abstract] [Full Text] [Related]

  • 5. Post-chemotherapeutic administration of interleukin-12 retards tumor growth and enhances immune cell function: combination therapy using paclitaxel and IL-12.
    Pressley JS, Elgert KD.
    Cancer Invest; 2006 Jun 01; 24(4):351-9. PubMed ID: 16777686
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Combined immunogene therapy of IL-6 and IL-15 enhances anti-tumor activity through augmented NK cytotoxicity.
    Lin CY, Chuang TF, Liao KW, Huang YJ, Pai CC, Chu RM.
    Cancer Lett; 2008 Dec 18; 272(2):285-95. PubMed ID: 18760876
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Transforming growth factor-beta1 blocks in vitro cardiac myocyte depression induced by tumor necrosis factor-alpha, interleukin-1beta, and human septic shock serum.
    Kumar A, Kumar A, Paladugu B, Mensing J, Parrillo JE.
    Crit Care Med; 2007 Feb 18; 35(2):358-64. PubMed ID: 17204997
    [Abstract] [Full Text] [Related]

  • 17. Transforming growth factor-beta up-regulates CD40-engaged IL-12 production of mouse Langerhans cells.
    Tada Y, Asahina A, Nakamura K, Miyazono K, Tomura M, Fujiwara H, Tamaki K.
    Eur J Immunol; 2001 Jan 18; 31(1):294-300. PubMed ID: 11265646
    [Abstract] [Full Text] [Related]

  • 18. TGF-beta1 acts as a tumor suppressor of human malignant keratinocytes independently of Smad 4 expression and ligand-induced G(1) arrest.
    Paterson IC, Davies M, Stone A, Huntley S, Smith E, Pring M, Eveson JW, Robinson CM, Parkinson EK, Prime SS.
    Oncogene; 2002 Feb 28; 21(10):1616-24. PubMed ID: 11896591
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Transforming growth factor-beta1 activates interleukin-6 expression in prostate cancer cells through the synergistic collaboration of the Smad2, p38-NF-kappaB, JNK, and Ras signaling pathways.
    Park JI, Lee MG, Cho K, Park BJ, Chae KS, Byun DS, Ryu BK, Park YK, Chi SG.
    Oncogene; 2003 Jul 10; 22(28):4314-32. PubMed ID: 12853969
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 3.